이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Flexibility, Resistance, Aerobic, Movement Execution Training in Adults With Hereditary Spastic Paraplegia (FRAME)

2026년 11월 3일 업데이트: IRCCS Eugenio Medea

Flexibility, Resistance, Aerobic, Movement Execution (FRAME) Training Program to Improve Gait Capacity in Adults With Hereditary Spastic Paraplegia: Protocol for a Single-cohort Feasibility Trial

Hereditary Spastic Paraplegia (HSP) is a group of inherited neurological disorders that cause progressive weakness and stiffness (spasticity) in the legs, reducing balance and walking ability. At present, there are no structured rehabilitation programs specifically designed to improve walking in people with HSP.

This study aims to find out whether a structured, therapist-guided exercise program called FRAME training can be delivered successfully to people with HSP, and whether it may help improve their walking. The program combines flexibility, muscle strengthening, motor control, balance and aerobic exercises. At the end of the program, participants receive a written manual and video tutorials to help them keep exercising at home.

연구 개요

상세 설명

Hereditary Spastic Paraplegia (HSP) is a heterogeneous group of inherited neurological disorders. It is characterized by progressive lower-limb weakness and spasticity that significantly impair walking endurance and speed. Several interventions have been studied for specific impairments, but there are still no comprehensive, structured neurorehabilitation programs designed to improve walking function in this population. This study explores a composite training approach (FRAME) that addresses the main factors limiting gait in HSP: reduced flexibility, muscle weakness, impaired motor control and balance, and low aerobic capacity.

Participants attend 10 to 16 therapist-guided sessions of 60 to 120 minutes, once or twice a week according to individual preferences and capabilities. Each session may include four components:

  1. Flexibility: stretching of the muscles typically affected by spasticity (triceps surae, adductors, rectus femoris, hamstrings), combined with biphasic high-frequency sensory electrical stimulation (100 Hz, 200 µs, intensity just below motor threshold, 30 minutes) to reduce muscle tone and enhance mobility.
  2. Resistance training and balance: strengthening of the muscles typically weakened in HSP, especially the proximal hip and trunk muscles. Core stability and resistance exercises are performed in sitting or standing under mild instability to promote muscle activation, balance and coordination.
  3. Movement execution and balance: gait training based on motor learning principles (repetitive task-oriented practice, variable practice, graded practice), with standing balance challenges and varied walking tasks (fast, slow, sideways and backward walking, stair climbing).
  4. Aerobic training: high-intensity interval training (HIIT), which has been shown to produce greater cardiovascular benefits than moderate-intensity exercise at a lower perceived effort. HIIT includes a 5-minute warm-up, two sets of 10 intervals (30 seconds high intensity / 30 seconds passive rest) with 5 minutes of rest between sets, and a 5-minute cool-down. The exercise mode (walking, running, cycling or squatting) is chosen to suit each participant.

At the end of the program, participants receive a transfer package (written manual and video tutorials) to support long-term home exercise.

This study is expected to give clinicians insight into whether a comprehensive, clinically oriented program can be delivered to adults with HSP and how much it may help them walk better. It will also inform future translational research in this field.

연구 유형

중재적

등록 (실제)

20

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Lombardy
      • Bosisio Parini, Lombardy, 이탈리아, 23842
        • Scientific Institute, IRCCS E. Medea, Department of Bosisio Parini, Lecco, Italy.
    • Veneto
      • Pieve di Soligo, Veneto, 이탈리아, 31053
        • Scientific Institute, IRCCS E. Medea, Department of Pieve di Soligo, Treviso, Italy

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults diagnosed with Hereditary Spastic Paraplegia.
  • Presence of any functional deficit in the lower limbs that affects walking, such as muscle weakness, hypertonia, or balance issues.
  • Ability to walk without the need for physical contact with another person, as defined by a Functional Ambulation Category score of 3 or higher.
  • Ability to understand simple instructions, comprehend the purpose of the study, willingness to participate and undergo at least 10 treatment sessions, eligible and willing to sign the informed consent.

Exclusion Criteria:

  • Botulinum toxin or surgery to treat lower limb hypertonia in the six months prior to enrollment in the study.
  • Contraindications for moderate physical activity, such as stretching exercises, muscle strength training, and aerobic capacity training.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: HSP Cohort

The whole cohort of HSP patients will receive the same comprehensive neurorehabilitation program aiming at improving gait capabilities (speed and endurance). The content and the dose of the treatment will be personalized according to patient's specific needs and preferences.

Flexibility: static and dynamic stretching combined with sensory, high-frequency electrical stimulation to reduce spasticity and improve mobility.

Resistance training: core stability and lower limb strength training in conditions of instability, to improve strength, coordination, and balance.

Movement execution training: gait training according to motor learning principles.

Aerobic exercise: in the form of high-intensity interval training at the end of each session, to improve cardiovascular status and foster motor learning consolidation (probably due to the release of brain derived neurotrophic factors).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Feasibility (recruitment rate).
기간: From study start up to 24 months.

Study feasibility in terms of achieving sufficient recruitment rate, defined as the enrollment of 20 patients within 24 months from the start of the study.

From study start up to 24 months.
Feasibility (adherence rate).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

Study feasibility in terms of achieving adequate adherence to the treatment plan, defined as completing at least 75% of the scheduled treatment sessions, and in any case a minimum of 10 treatment sessions.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1).
Feasibility (retention rate).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

Study feasibility in terms of achieving sufficient patient retention, defined as at least 75% of the enrolled patients completing the study with adequate adherence to the treatment.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1).
Feasibility (safety).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

Study feasibility in terms of absence of any serious adverse event related to patient participation in the study.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

2차 결과 측정

결과 측정
측정값 설명
기간
Six Minute Walking Test (6MWT).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The 6MWT is a clinical assessment of gait endurance, by measuring the distance covered (metres) while walking on a straight even path (30 meters) for six minutes. According to original instructions, the patient is asked to walk along the path as fast as possible, taking turns at the edges of the path. Patients are allowed to walk autonomously or with assistive devices and to rest by standing.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Ten Metre Walk Test (10MWT).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The 10MWT is used to assess walking speed in meters/second (m/s) over a short distance. The total time taken to walk six meters (the central portion of a 10-meter walkway) is recorded to the nearest hundredth of a second. 6 meters is then divided by the total time taken to ambulate and recorded in m/s.

Two trials at comfortable pace are performed, followed by two trials at fast pace. Averages (one for comfortable pace, one for fast pace) are recorded.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

기타 결과 측정

결과 측정
측정값 설명
기간
Passive range of motion.
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

An inclinometer will be used to measure the passive range of motion for ankle dorsiflexion, knee flexion, hip abduction, and hip extension, on both sides.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Hereditary Spastic Paraplegia - Self Notion and Perception Questionnaire (HSP-SNAP).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

HSP-SNAP is a questionnaire used to assess the self-perception of individuals diagnosed with hereditary spastic paraplegia (HSP).

HSP-SNAP includes 12 questions, with 2 items dedicated to each symptom dimension (stiffness, weakness, imbalance, reduced endurance, fatigue, and pain). Each pair of items for a given dimension includes both positive and negative responses to prevent automatic answers. The HSP-SNAP employs a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree). To account for both positive and negative items, scoring is as follows: for items with a positive tone, the score is calculated as "patient's score minus 1" (pt score-1); for negative items, the score is "5 minus the patient's score" (5-pt score). The overall score is the sum of all item scores, ranging from 0 to 48. A higher score indicates better well-being and milder symptoms.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Functional Reach Test (FRT).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

FRT evaluates dynamic balance while standing. Patient is asked to stand with one shoulder flexed at 90 degrees and the hand making a fist, and then to bend forward up to the limit of balance, right before taking a step to prevent falling. A horizontal ruler taped on the wall is used to measure the difference in position of the head of the third metacarpal bone from starting to end position. Patients are not allowed to touch the wall or rotate the trunk while bending forward.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Five times Sit-to-Stand (5TSTS).
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The 5TSTS test is an assessment to evaluate lower body strength, balance, and functional mobility. The test involves the participant sitting in a chair, then standing up and sitting down five times as quickly as possible, without using their arms for assistance. The time taken to complete the five repetitions is recorded.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
modified Spastic Paraplegia Rating Scale (mSPRS)
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The mSPRS is a clinical assessment tool used to evaluate the severity and progression of symptoms in individuals with hereditary spastic paraplegia. The scale measures aspects such as spasticity, mobility, and functional abilities related to walking, balance, and limb function.

The mSPRS has a scoring range from 0 to 28, with higher scores on the mSPRS indicating more severe symptoms and greater impairment in motor function and spasticity.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Stabilometric platform.
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

With the patient standing over a stabilometric platform, two kinematic assessments will be performed: (1) static stance, by standing for 30 seconds with eyes open and 30 seconds with eyes closed; (2) limits of stability, by bending with the body in different direction, displacing the centre of mass towards anterior, posterior, and lateral targets projected on a screen in front of the patient.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Isometric strength.
기간: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

A dynamometer will be used to measure isometric strength for ankle dorsiflexors, ankle plantarflexors, knee extensors, knee flexors, hip extensors, hip flexors, hip abductors, on both sides.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Leonardo Boccuni, PhD, Scientific Institute, IRCCS E. Medea, Department of Conegliano, Treviso, Italy.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 23일

기본 완료 (추정된)

2027년 1월 1일

연구 완료 (추정된)

2027년 4월 30일

연구 등록 날짜

최초 제출

2024년 12월 12일

QC 기준을 충족하는 최초 제출

2024년 12월 18일

처음 게시됨 (실제)

2024년 12월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Anonymized individual participant data will be shared with other researchers upon reasonable request.

IPD 공유 기간

Start Date: June 2027. End Date: June 2037.

IPD 공유 액세스 기준

Any researcher accredited by non-profit clinical and research centre.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • ANALYTIC_CODE
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다